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Methods and Results To evaluate whether levels of D-dimer are associated with the occurrence of future myocardial infarction (MI) among apparently healthy men, levels were measured in plasma samples collected at baseline from 296 participants in the Physicians' Health Study who later developed a first MI and from an equal number of age-and smoking status-matched control subjects who remained free of vascular disease during a mean follow-up period of 60.2 months. In univariate analyses, baseline plasma concentrations of D-dimer in the upper ranges of normal were associated with elevated risks of MI. Specifically, the relative risk of future MI for individuals with baseline D-dimer concentration exceeding the 95th percentile of the control distribution was two times higher than that of individuals with lower levels (relative risk [ Conclusions Elevated levels of D-dimer are associated with increased risks of future MI, although they do not appear to be an independent predictor when other risk factors are considered. As the presence of D-dimer in plasma reflects ongoing fibrin degradation, these data support the hypothesis that activation of the endogenous fibrinolytic system occurs many years in advance of coronary arterial occlusion. 
Methods
We performed a nested case-control study using prospectively collected plasma samples from a cohort of apparently healthy men participating in the Physicians' Health Study,'8 a randomized, double-blind, placebo-controlled trial of aspirin and beta-carotene in the primary prevention of cardiovascular disease and cancer. The details of the Physicians' Health Study"8 have been presented previously; in brief, 22 071 US male physicians aged 40 to 84 years and free of prior MI, stroke, transient ischemic attack, or cancer were randomly assigned in a 2x2 factorial design to one of four treatment groups: 325 mg aspirin on alternate days (supplied as Bufferin by Bristol Myers Products), 50 mg beta-carotene on alternate days (supplied as Lurotin by BASF), both, or neither. Six months after randomization and annually thereafter, questionnaires assessing risk factors and disease outcomes were mailed and returned by these physicians with 99.7% follow-up for morbidity and 100% for mortality.
At enrollment, all potentially eligible men were assigned to a regimen of active aspirin and placebo beta-carotene in an 18-week run-in to identify good compliers for long-term follow-up. During the run-in, all participants were asked to provide baseline blood plasma samples. Blood collection kits including EDTA Vacutainer tubes and plastic collection vials were sent to each participant along with instructions for blood drawing. Participants were asked to have blood drawn into the EDTA tubes, centrifuge the tubes, and return the plasma, accompanied by cold pack, by overnight courier. On arrival in the laboratory, specimens were placed in aliquots and stored at -80°C. Of 22 071 physicians randomized, 14 916 returned a baseline blood sample specimen (68%). No specimens were inadvertently thawed or even warmed appreciably during storage.
Hospital records were requested for all reported cases of fatal and nonfatal MI occurring after randomization. These medical records, death certificates, and autopsy reports were reviewed by an end points committee of physicians using standardized criteria to confirm or refute each reported event.
The diagnosis was considered confirmed if the reported event met the World Health Organization criteria for MI, which include symptoms plus either elevations of cardiac enzyme levels or diagnostic changes on the ECG.'9 For fatal MIs, we also accepted diagnoses based on autopsies and deaths confirmed by records as due to coronary heart disease (International Classification of Diseases codes 411 to 414). Silent MI discovered on routine examination was not included since it could not be assigned an accurate date of occurrence. Sudden deaths in men with no history of coronary disease were not included unless coronary disease could be confirmed as the cause of death.
Using a nested case-control design, each physician who provided an adequate baseline plasma blood sample and had a confirmed MI after randomization was matched to one control subject. Only the first MI was considered in any individual.
Control subjects were randomized physicians who provided a baseline plasma sample and did not report cardiovascular disease at the time infarction occurred in the patient. Control subjects were selected at random from participants who met the matching criteria of age (+ 1 year), smoking habit (current, past, or never-smoker), and time since randomization by 6-month intervals.
For each patient (case) and each control subject, plasma collected and stored at baseline was thawed and assayed for D-dimer using an ELISA with TintElize D-dimer kits produced Results Table 1 displays baseline characteristics of the 296 case-control pairs. As previously reported for this cohort,21 patients had higher mean cholesterol and lower mean HDL cholesterol levels than control subjects. In addition, patients had a higher mean body mass index, exercised less frequently, and were more likely to have a parental history of MI or a personal history of diabetes.
As expected, because both patients and control subjects were healthy at the time of blood collection, baseline levels of D-dimer for >98% of the sample were within normal limits, and only two values (one patient and one control) were above cutoff points clinically considered to be associated with an increased probabil- To assess for any potential linear relations between D-dimer and other measured atherosclerotic and/or thrombotic risk factors in this study population, unadjusted and age-adjusted correlation coefficients were computed and are displayed in Table 4 . As shown, no statistically significant correlations were found between baseline D-dimer concentration and total or HDL cholesterol, Lp(a), TPA, or PAI-1.
Discussion
In univariate analysis of these prospective data, apparently healthy men with baseline plasma concentrations of D-dimer exceeding the 95th percentile of the control distribution (.107 ng/mL) had twice the risk of future MI than men with lower levels. This association persisted in multivariate analyses controlling for nonlipid risk factors and for Lp(a) but was no longer statistically significant in analyses adjusting for total and HDL cholesterol or for endogenous TPA and PAI-1 antigen levels.
We are aware of no prior data assessing the relation between D-dimer levels and risk of future MI among D-Dimer Concentration, ng/ml (percenile of control distribution) Bar graph shows relative risks of future myocardial infarction associated with baseline plasma concentration of cross-linked fibrin degradation product, measured as D-dimer. A statistically significant increase in risk is present for those individuals with baseline D-dimer levels exceeding 107 ng/mL, the 95th percentile cutoff point of the control distribution.
otherwise healthy men. However, the current data are consistent with recent work demonstrating an association between increased levels of D-dimer and cardiovascular risk among patients with known atherosclerosis. 24 In that study, the relative risk of coronary events among patients with symptomatic peripheral arterial disease was 4.4 times higher for subjects with D-dimer levels in the highest quintile (2179 ng/mL) than for subjects with levels in the lowest quintile (<65 ng/mL). Although the higher relative risk in that study may indicate that patients with prevalent arteriosclerotic disease are more likely to have elevated fibrin turnover than asymptomatic individuals, it is also possible that this difference (Figure) .
The finding in these data of a positive association between baseline D-dimer concentration and risk of a first MI supports the hypothesis that activation of the endogenous fibrinolytic system occurs several years in advance of coronary occlusion.10""1,25 In addition, these data are potentially important in understanding the pathophysiology of thrombotic occlusion since the presence of D-dimer implies ongoing formation and degradation of fibrin and thus may help to explain the mechanism by which elevated levels of fibrinogen appear to be a marker of risk for cardiovascular events.1-32627 Future work will be required to identify the source of the cross-linked fibrin degradation products in these apparently healthy men. In this regard, it is possible that the elevated levels of D-dimer found in our study may reflect increased fibrin turnover among individuals with elevated levels of circulating fibrin. On the other hand, since D-dimer is present in arterial thrombi and fibrin is a major component of atherosclerotic plaque, it is also possible that the elevations of D-dimer found in our study are a consequence of important preclinical atherosclerosis.
Potential limitations of the present study merit consideration. For example, although elevations of D-dimer have been reported among patients with acute MI,28 the prospective design of our study rules out the possibility that increased concentrations of D-dimer are a result of infarction and markedly reduces the possibility of bias in the selection of control subjects. Altered D-dimer concentrations due to the long storage period before assay also appear to be an unlikely source of bias as the mean (48.9 ng/mL) and median (37.0 ng/mL) D-dimer levels among our control subjects are consistent with prior studies of D-dimer among healthy populations. [15] [16] [17] 29 In addition, because patient and control samples were stored for the same amount of time and handled identically throughout the study, systematic bias based on case status is improbable. Finally, it is important to point out that random misclassification cannot explain our findings as the presence of this effect would, if anything, lead to an underestimation of the true association.
In sum, these data indicate that baseline plasma D-dimer levels at the upper end of the normal distribution are associated with increased risks of future MI among apparently healthy men. This finding is consistent with a major role for fibrinogen and fibrin in the pathogenesis of atherosclerosis and supports the hypothesis that baseline assessment of hemostatic and thrombotic parameters may serve as markers of risk for future MI.30
